Hyperlipidemia and the rheumatic diseases

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Premature atherosclerosis is a recognized complication of systemic lupus erythematosus. Atherosclerosis begins in the pediatric age group, and interventions directed toward prevention should begin in childhood as well. A possible cause of premature atherosclerosis is dyslipoproteinemia from the underlying chronic inflammatory disease or from corticosteroid therapy. A relationship between dyslipoproteinemia and anticardiolipin antibodies has been demonstrated. Dietary therapy is helpful, but many patients continue to have significant dyslipoproteinemia after both dietary modification and fish oil supplementation. Lipid-lowering drugs may be indicated in this subgroup. Potential mechanisms of dyslipoproteinemia are discussed.

Original languageEnglish (US)
Pages (from-to)455-458
Number of pages4
JournalCurrent Opinion in Rheumatology
Volume8
Issue number5
StatePublished - 1996
Externally publishedYes

Fingerprint

Dyslipidemias
Hyperlipidemias
Rheumatic Diseases
Atherosclerosis
Unsaturated Dietary Fats
Diet Therapy
Anticardiolipin Antibodies
Fish Oils
Systemic Lupus Erythematosus
Adrenal Cortex Hormones
Chronic Disease
Age Groups
Pediatrics
Lipids
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Hyperlipidemia and the rheumatic diseases. / Ilowite, Norman Todd.

In: Current Opinion in Rheumatology, Vol. 8, No. 5, 1996, p. 455-458.

Research output: Contribution to journalArticle

@article{c5e1d3ac4d9c44958c19ad8c15c13566,
title = "Hyperlipidemia and the rheumatic diseases",
abstract = "Premature atherosclerosis is a recognized complication of systemic lupus erythematosus. Atherosclerosis begins in the pediatric age group, and interventions directed toward prevention should begin in childhood as well. A possible cause of premature atherosclerosis is dyslipoproteinemia from the underlying chronic inflammatory disease or from corticosteroid therapy. A relationship between dyslipoproteinemia and anticardiolipin antibodies has been demonstrated. Dietary therapy is helpful, but many patients continue to have significant dyslipoproteinemia after both dietary modification and fish oil supplementation. Lipid-lowering drugs may be indicated in this subgroup. Potential mechanisms of dyslipoproteinemia are discussed.",
author = "Ilowite, {Norman Todd}",
year = "1996",
language = "English (US)",
volume = "8",
pages = "455--458",
journal = "Current Opinion in Rheumatology",
issn = "1040-8711",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Hyperlipidemia and the rheumatic diseases

AU - Ilowite, Norman Todd

PY - 1996

Y1 - 1996

N2 - Premature atherosclerosis is a recognized complication of systemic lupus erythematosus. Atherosclerosis begins in the pediatric age group, and interventions directed toward prevention should begin in childhood as well. A possible cause of premature atherosclerosis is dyslipoproteinemia from the underlying chronic inflammatory disease or from corticosteroid therapy. A relationship between dyslipoproteinemia and anticardiolipin antibodies has been demonstrated. Dietary therapy is helpful, but many patients continue to have significant dyslipoproteinemia after both dietary modification and fish oil supplementation. Lipid-lowering drugs may be indicated in this subgroup. Potential mechanisms of dyslipoproteinemia are discussed.

AB - Premature atherosclerosis is a recognized complication of systemic lupus erythematosus. Atherosclerosis begins in the pediatric age group, and interventions directed toward prevention should begin in childhood as well. A possible cause of premature atherosclerosis is dyslipoproteinemia from the underlying chronic inflammatory disease or from corticosteroid therapy. A relationship between dyslipoproteinemia and anticardiolipin antibodies has been demonstrated. Dietary therapy is helpful, but many patients continue to have significant dyslipoproteinemia after both dietary modification and fish oil supplementation. Lipid-lowering drugs may be indicated in this subgroup. Potential mechanisms of dyslipoproteinemia are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0029835902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029835902&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 455

EP - 458

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

SN - 1040-8711

IS - 5

ER -